Welcome to our dedicated page for Abbvie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AbbVie Inc. filings document formal disclosures for a global pharmaceutical issuer with common stock and multiple senior note series registered on the New York Stock Exchange. Recent Form 8-K reports cover quarterly and annual results, preliminary earnings impacts from acquired IPR&D and milestone expenses, material-event disclosures, material agreements and capital-structure updates.
The company’s filing record also includes debt-financing disclosures for completed senior note offerings and definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items. These documents provide regulatory detail on AbbVie’s operating results, listed securities, governance framework and financing activity.
AbbVie Inc. is offering $8,000,000,000 aggregate principal amount of senior notes across seven series.
The offering includes floating rate notes due 2028 and six fixed‑rate series maturing from 2028 to 2066, with coupons ranging from 3.775% to 5.650%. The issuer expects net proceeds of approximately $7.95 billion, which it intends to use to repay amounts outstanding under its 364‑Day Delayed Draw Term Loan Facility (of which $2.0 billion is currently outstanding) and for general corporate purposes, which may include repayment or repurchase of outstanding debt.
AbbVie Inc. is marketing a multi-series offering of senior unsecured notes, including a floating-rate series linked to Compounded SOFR and several fixed-rate series, under a preliminary prospectus supplement dated February 24, 2026. The company states it intends to use proceeds to repay borrowings under its 364-Day Delayed Draw Term Loan Facility, of which $2.0 billion is outstanding, and for general corporate purposes. The notes will be unsecured, rank equally with existing unsecured senior debt, be issued in minimum denominations of $2,000, and may be redeemed at AbbVie’s option on the terms described in the prospectus supplement.
AbbVie Inc. reported that EVP, R&D and CSO Roopal Thakkar acquired new equity awards through grants rather than open-market trades. On February 18, 2026, Thakkar received an employee stock option for 21,937 AbbVie shares, exercisable in three annual installments of 7,313, 7,312 and 7,312 shares in 2027, 2028 and 2029.
On the same date, Thakkar also acquired several performance-based AbbVie common stock awards, including grants of 6,015, 2,138, 3,346 and 6,638 shares. These awards were tied to performance goals such as earnings per share, relative total shareholder return and relative return on equity. The Compensation Committee certified that the goals were met, releasing the performance-vesting restrictions, with the shares scheduled to be issued on February 28, 2026.
AbbVie Inc. senior vice president and controller David Ryan Purdue reported multiple equity awards and holdings changes. On February 18, 2026, he acquired an option to buy 4,875 shares of AbbVie common stock at an exercise price set by the company’s incentive plan, recorded at $0.00 per share for reporting purposes.
On the same date, he also acquired several blocks of AbbVie common stock as grants or awards: 2,505 shares, 890 shares, 1,292 shares, and 1,384 shares, all reported at $0.00 per share as they were issued under performance-based share and restricted stock unit awards. Footnotes explain these awards were tied to earnings per share, relative total shareholder return, and relative return on equity goals, with vesting confirmed by AbbVie’s Compensation Committee and the shares scheduled to be issued on February 28, 2026.
The filing also notes 543 shares of AbbVie common stock held indirectly through a profit sharing trust as part of the AbbVie savings program as of February 20, 2026, including shares acquired via dividend reinvestment. The employee stock option vests in annual increments of 1,625 shares on February 18 of 2027, 2028, and 2029.
AbbVie Inc. executive Jeffrey Ryan Stewart, EVP and Chief Commercial Officer, reported awards of stock options and performance-based shares on February 18, 2026. He acquired an option to buy 26,812 shares that vests in three annual installments starting in February 2027, plus multiple performance-vesting stock and restricted stock unit awards tied to earnings per share, relative total shareholder return, and relative return on equity, with shares scheduled to be issued on February 28, 2026. An additional 1,338 shares are held indirectly by his spouse in a trust, for which he disclaims beneficial ownership.
AbbVie Inc. executive Perry C. Siatis, EVP, GC and Secretary, reported multiple equity awards in AbbVie common stock. On February 18, 2026, he acquired several performance-based share awards, including 5,792, 5,628, 5,808 and 16,290 shares, all at a stated price of $0.00 per share.
Footnotes explain these represent performance-vesting awards and restricted stock units granted in 2023, 2024 and 2025, tied to earnings per share, relative total shareholder return and relative return on equity. The performance conditions were certified as achieved, and the related shares are scheduled to be issued on February 28, 2026. He also received an employee stock option covering 19,500 shares, vesting in three equal annual installments starting in 2027.
AbbVie Inc. executive vice president and chief operations officer Azita Saleki-Gerhardt reported equity compensation grants. She received an employee stock option for 20,312 shares at a grant price of $0.00, vesting in three annual installments of 6,771, 6,771 and 6,770 shares on February 18, 2027, February 18, 2028, and February 18, 2029.
She also acquired multiple blocks of AbbVie common stock through performance-based share and restricted stock unit awards, with grants from February 16, 2023, February 15, 2024, and February 13, 2025 tied to earnings per share, relative total shareholder return, and relative return on equity. These performance-vesting restrictions were certified as attained on February 18, 2026, and the shares will be issued on February 28, 2026. Additional indirect holdings include shares in an AbbVie savings program and shares held by her spouse, for which she disclaims beneficial ownership.
AbbVie Inc. executive Demetris D. Crum, EVP and Chief HR Officer, reported equity compensation awards rather than open-market trades. On February 18, 2026, Crum was granted options for 13,406 shares of AbbVie common stock under the AbbVie Amended and Restated 2013 Incentive Stock Program. These options become exercisable in three annual installments of 4,469 shares on February 18, 2027, 4,469 shares on February 18, 2028, and 4,468 shares on February 18, 2029.
Crum also acquired 1,216 shares and 1,244 shares of AbbVie common stock tied to performance-vesting restricted stock unit awards originally granted on February 15, 2024 and February 13, 2025, respectively. These awards vest based on a relative return on equity measure, with performance certified by AbbVie’s Compensation Committee, and the shares are scheduled to be issued on February 28, 2026.
AbbVie executive Nicholas Donoghoe reported multiple equity awards tied to performance goals. On February 18, 2026, he acquired an option to buy 20,312 AbbVie shares, vesting in three equal annual installments starting on February 18, 2027.
He also received performance-based stock awards of 13,031, 4,632, 5,172 and 6,222 AbbVie shares. These stock units vested after AbbVie’s Compensation Committee certified achievements in earnings per share, relative total shareholder return and relative return on equity, with shares scheduled to be issued on February 28, 2026.